Alset Inc. (NASDAQ:AEI – Get Free Report) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,400 shares, a decline of 89.2% from the October 31st total of 13,000 shares. Approximately 0.1% of the company’s stock are short sold. Based on an average daily trading volume, of 41,500 shares, the short-interest ratio is presently 0.0 days.
Insider Transactions at Alset
In other news, CEO Heng Fai Ambrose Chan purchased 6,034,537 shares of the stock in a transaction on Tuesday, September 24th. The stock was bought at an average price of $0.63 per share, with a total value of $3,801,758.31. Following the transaction, the chief executive officer now owns 19,264,692 shares in the company, valued at $12,136,755.96. The trade was a 45.61 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 66.70% of the company’s stock.
Alset Stock Up 12.0 %
Shares of Alset stock traded up $0.13 on Wednesday, reaching $1.21. 52,622 shares of the stock were exchanged, compared to its average volume of 67,043. The business has a 50 day moving average price of $1.40 and a two-hundred day moving average price of $1.20. The firm has a market capitalization of $11.18 million, a price-to-earnings ratio of -0.28 and a beta of 1.26. Alset has a twelve month low of $0.46 and a twelve month high of $2.05.
Alset Company Profile
Alset Inc engages in the real estate development, financial services, digital transformation technologies, biohealth activities, and consumer products businesses in the United States, Singapore, Hong Kong, Australia, and South Korea. It operates through four segments: Real Estate, Digital Transformation Technology, Biohealth, and Other Business Activities segments.
Recommended Stories
- Five stocks we like better than Alset
- What Are the U.K. Market Holidays? How to Invest and Trade
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- 5 discounted opportunities for dividend growth investors
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Are These Companies Considered Blue Chips?
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Alset Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alset and related companies with MarketBeat.com's FREE daily email newsletter.